Nervonik Successfully Completes Preclinical Testing of Neural Sensing During Peripheral Nerve Stimulation (PNS) in Large Animal Models

Proprietary waveform and hardware enable real-time neural sensing during stimulation, paving the way for multiple bio-sensing innovations in Peripheral Nerve Stimulation, including future closed-loop therapies.

LOS ANGELES, Sept. 16, 2025 /PRNewswire/ -- Nervonik Inc., a neuromodulation company pioneering advanced Peripheral Nerve Stimulation (PNS) technologies, announced today that it has successfully completed key milestones in preclinical testing of its proprietary ECAP (Evoked Compound Action Potential) and CMAP (Compound Muscle Action Potential) sensing capabilities in large animal models.

This breakthrough demonstrates that Nervonik's proprietary waveform design and hardware platform can sense neural activity during active stimulation, a critical milestone toward enabling optimized lead placement, optimized programming, and closed-loop PNS therapy. This advancement is expected to enhance therapy precision, improve patient outcomes, reduce energy requirements, and accelerate the path toward clinical translation. Data will be shared early next year in leading conferences such as North American Neuromodulation Society (NANS) conference.

"This achievement validates the unique potential of Nervonik's platform in peripheral nerve stimulation," said Dr. Aydin Babakhani, CEO of Nervonik. "By combining precise sensing with targeted stimulation, we are building the foundation for therapies that are more adaptive, effective, and patient-specific."

"Our proprietary ECAP and CMAP sensing technology allows us to see what nerves and muscles are doing in real-time while therapy is being delivered," said Dr. Jeff Kramer, Chief Scientific Officer of Nervonik. "This capability will be transformative in optimizing stimulation parameters and personalizing PNS therapy."

"We have seen biosensing produce enhanced clinical outcomes in other neuromodulation therapies and so adding this capability to PNS is a next big technological step. These results are very encouraging, and I am looking forward to working with the Nervonik team in translating this to enhance pain management patient care," said Dr. Timothy Deer, President and CEO of The Spine and Nerve Centers of the Virginias, who is also a member of the clinical advisory team at Nervonik.

Nervonik's PNS platform is designed to address the limitations of current systems by integrating advanced custom hardware, wireless interfaces, and proprietary waveforms. The company is next focused on FDA submission and early commercialization milestones.

For more information, please visit www.nervonik.com.

About Nervonik
Nervonik Inc. is a neuromodulation company focused on developing advanced Peripheral Nerve Stimulation (PNS) technologies for the treatment of chronic pain and other neurological conditions. Leveraging proprietary waveforms, bio-sensing, and miniaturized low-power implantable hardware, Nervonik is redefining the future of neuromodulation therapy.

SOURCE Nervonik Inc.